Skip to main content

Table 1 Baseline demographic characteristics in the double-blind controlled study

From: ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

  Placebo ABT-126 25 mg ABT-126 50 mg ABT-126 75 mg Donepezil 10 mg All subjects
Number of subjects 104 77 107 73 75 436
 Age (years), mean ± SD 73.2 ± 7.39 73.0 ± 7.62 73.9 ± 8.26 76.2 ± 8.14 75.1 ± 7.75 74.2 ± 7.89
 Age < 75 years, n (%) 59 (56.7) 37 (48.1) 50 (46.7) 30 (41.1) 30 (40.0) 206 (47.2)
 Age ≥ 75 years, n (%) 45 (43.3) 40 (51.9) 57 (53.3) 43 (58.9) 45 (60.0) 230 (52.8)
 Female, n (%) 65 (62.5) 40 (51.9) 68 (63.6) 52 (71.2) 40 (53.3) 265 (60.8)
 Male, n (%) 39 (37.5) 37 (48.1) 39 (36.4) 21 (28.8) 35 (46.7) 171 (39.2)
 White, n (%) 91 (87.5) 75 (97.4) 96 (89.7) 64 (87.7) 70 (93.3) 396 (90.8)
 BMI (kg/m2), mean ± SD 26.2 ± 3.88 27.1 ± 4.91 26.0 ± 4.98 25.5 ± 4.62 25.0 ± 4.27 26.0 ± 4.57
 Age at AD symptom onset (years), mean ± SD 69.6 ± 7.66 69.2 ± 8.51 70.2 ± 8.67 72.3 ± 7.97 71.2 ± 8.24 70.4 ± 8.25
 Years since AD symptom onset,a mean ± SD 3.7 ± 2.61 4.1 ± 2.96 3.9 ± 3.11 4.2 ± 2.67 4.2 ± 2.45 4.0 ± 2.78
 Age at AD diagnosis (years), mean ± SD 72.1 ± 7.60 71.5 ± 8.10 72.5 ± 8.64 74.8 ± 8.30 73.6 ± 7.91 72.8 ± 8.16
 Years since AD diagnosis, mean ± SD 1.1 ± 1.79 1.5 ± 1.91 1.4 ± 2.37 1.5 ± 1.96 1.6 ± 1.92 1.4 ± 2.02
 Family history of AD, n (%) 22 (21.2) 20 (26.0) 23 (21.5) 6 (8.2 %) 10 (13.3) 81 (18.6)
 ADAS-Cog (11-item),b mean ± SD 26.1 ± 10.98 24.6 ± 11.45 25.6 ± 11.32 27.2 ± 9.81 27.9 ± 12.08 26.2 ± 11.16
 MMSE score, mean ± SD 19.1 ± 4.00 20.0 ± 4.09 18.6 ± 4.03 18.6 ± 3.87 18.4 ± 4.42 18.9 ± 4.09
Number of subjects 92 66 97 63 64 382
 APOE ε4 positive, n (%) 37 (40.2) 34 (51.5) 48 (49.5) 27 (42.9) 32 (50.0) 178 (46.6)
  1. aTime from onset of AD symptoms or diagnosis to first dose of study drug
  2. bBaseline results based on a total of 435 subjects
  3. AD Alzheimer’s dementia, ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive subscale, APOE apolipoprotein E, BMI body mass index, MMSE Mini-Mental Status Examination, SD standard deviation